CDMRP: FY26 Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP), managed by the Congressionally Directed Medical Research Programs (CDMRP) under the Defense Health Agency Research and Development – Medical Research and Development Command, will support innovative, high-impact research with clinical relevance focused on improving the prevention, assessment, and treatment of psychological health conditions and traumatic brain injury (TBI).

The program has released a pre-announcement to allow investigators time to begin preparing research concepts. Funding opportunity announcements will be released later on Grants.gov, and those announcements will include the official submission deadlines.

Application deadlines are not specified in the pre-announcement.

Researchers developing clinical trials, translational research, or health services research related to psychological health and TBI in military populations should begin preparing now so they can move quickly once the official solicitations are released.

How much funding would I receive?

Funding depends on the award mechanism and research level selected.

Clinical Trial Award

• Research Level 1

  • Maximum funding: $2.1 million total costs

  • Period of performance: up to 4 years

• Research Level 2

  • Maximum funding: $4.1 million total costs

  • Period of performance: up to 4 years

Health Services Research Award

• Maximum funding: $4.0 million total costs

• Period of performance: up to 4 years

Translational Research Award

• Research Level 1

  • Maximum funding: $1.0 million total costs

  • Period of performance: up to 4 years

• Research Level 2

  • Maximum funding: $2.0 million total costs

  • Period of performance: up to 4 years

Total costs include both direct and indirect costs.

The pre-announcement does not specify the number of awards expected.

What could I use the funding for?

Projects must address psychological health conditions and/or traumatic brain injury (TBI) and fall within one of the program’s focus areas.

1. Understand

Research addressing knowledge gaps in epidemiology and etiology, including:

• Risk, protective, and biological factors affecting vulnerability, response, and long-term outcomes

• Sex as a biological variable

• Psychological health factors related to sexual harassment or assault perpetration, victimization, and barriers to reporting

2. Prevent and Assess

Research focused on prevention, screening, diagnosis, or prognosis, including:

• Identification and validation of biomarkers or objective assessment methods

• Tools supporting return-to-activity or return-to-duty decisions

• Prevention approaches for psychological health conditions and/or TBI

• Cross-cutting prevention strategies addressing outcomes such as:

  • Suicide

  • Interpersonal violence

  • Sexual assault

  • Psychological health conditions

  • TBI

• Solutions supporting military and family readiness and resilience

3. Treat

Research on novel or repurposed interventions, including:

• Treatments and rehabilitation approaches that promote sustained functional recovery

• Interventions across acute, post-acute, or chronic phases

• Postvention strategies following events such as suicide or sexual assault

• Health services research improving access to care, adoption of evidence-based practices, or treatment engagement

Are there any additional benefits I would receive?

• Being part of a CDMRP-managed research portfolio with a history of high-impact biomedical awards.

• Two-tier review that evaluates both scientific quality and programmatic relevance (once FOA is published).

What is the timeline to apply and when would I receive funding?

This announcement is a pre-announcement only intended to give researchers time to prepare proposals.

Key points:

• Funding opportunity announcements will be released on Grants.gov.

• Those announcements will include pre-application and application deadlines.

• Application deadlines are not specified in the pre-announcement.

Submission process:

• Pre-applications must be submitted through eBRAP (Electronic Biomedical Research Application Portal).

• Some mechanisms require preproposals or Letters of Intent before full applications.

• Full application submission may be by invitation only depending on the mechanism.

The pre-announcement does not specify when awards will be made.

Where does this funding come from?

Funding is provided under the Fiscal Year 2026 Defense Appropriations Act and administered by the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC) through the Congressionally Directed Medical Research Programs (CDMRP).

Who is eligible to apply?

Eligibility varies slightly by mechanism but generally includes:

• Independent investigators at any career level

Additional details:

• Postdoctoral fellows are not considered independent investigators

• Some mechanisms include an Early-Career Investigator Partnering Option that allows two principal investigators, where:

  • One PI must be within 10 years of completing their terminal degree at the application submission deadline

  • If funded, each PI receives an individual award within their recipient organization(s)

The solicitation does not specify eligible organization types in the pre-announcement.

What companies and projects are likely to win?

Projects likely to be competitive will:

• Address psychological health conditions and/or traumatic brain injury

• Demonstrate high clinical relevance to military populations

• Provide innovative, high-impact research approaches

• Advance solutions for prevention, diagnosis, treatment, or health system implementation

• Lead to health care products, technologies, or clinical practice guidelines

Specific program priorities include:

• Biomarkers and objective diagnostic methods

• Cross-cutting prevention approaches addressing multiple adverse outcomes

• Interventions that support sustained functional recovery

• Research improving access to care or adoption of evidence-based practices

Are there any restrictions I should know about?

Restrictions vary by award mechanism.

Key limitations include:

Clinical Trial Award

• Must support clinical trials

• Preproposal required

• Full application submission by invitation only

Health Services Research Award

• Clinical research and clinical trials allowed

• Trials for new treatments are prohibited

• Requires Letter of Intent prior to full application

Translational Research Award

• Supports high-risk, high-reward translational research

• Basic research prohibited

• Clinical trials prohibited

• Requires preproposal submission

• Full application submission by invitation only

All submissions must comply with the final funding opportunity announcements released on Grants.gov.

How long will it take me to prepare an application?

Preparation time will depend on the mechanism and project complexity.

Applicants should expect to prepare:

• A preproposal or Letter of Intent

• A full application if invited

The pre-announcement does not specify application preparation timelines.

How can BW&CO help?

BW&CO supports teams applying to CDMRP and Department of Defense research programs by:

• Determining program fit and mechanism selection

• Structuring projects to align with TBIPHRP focus areas and evaluation criteria

• Developing a competitive preproposal or Letter of Intent

• Preparing the full application package if invited

• Managing compliance with eBRAP and Grants.gov submission requirements

Because full applications may be invitation-only, strong early positioning during the preproposal stage is critical.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Environmental Exposure Detection Technologies and/or Decontamination Treatments for Military Working Dogs - SBIR DHA26BZ01-NV003

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop decontamination treatments for military working dogs that have been exposed to toxic industrial chemicals and materials through the performance of their duties.

Description:

This topic is in support of the DoD Working Dog Strategic Research Plan concerning mitigation, countermeasures and treatments for toxin/toxic exposures1. In modern military operations, military working dogs (MWDs) are at risk of exposure by many different types of hazardous materials. These include toxic industrial chemicals (TICs) and materials (TIMs) such as hydrocarbons, polychlorinated biphenyls, glycols, hazardous metals, gases (hydrogen cyanide, hydrogen sulfide, freon, carbon monoxide, etc.), acids and alkali substances. Techniques for the decontamination of hazardous material exposures to the surface of the MWD are well defined2,3,4. Although there are useful treatment options for external decontamination, there are few treatment options for toxic exposures that have been absorbed into the body of the MWD.

The objective of this topic is to develop new treatments for MWDs against hazardous materials that have been absorbed into the body either through the skin or mucous membranes, by inhalation, or ingestion. Current systemic treatments employed to care for MWDs include supportive antibiotic therapy for sulfur mustard, atropine injections for nerve agents, and Narcan for narcotics, but there are limited treatment options available for TIC/TIM exposures4,5,6. Systemic treatments for the MWD should be able to be performed by veterinarians and their support personnel (trained animal care specialists (68T) in Role 1 and/or veterinary medical and surgical teams (VMST) in Role 2). Potential MWD systemic treatments could include but are not limited to kits containing indicators or detectors of TIC/TIM exposure with easily identifiable injectable treatments for the identified contaminant (indicator/detector) and/or hemoperfusion systems and filters that can be used to remove contaminants from the blood (systemic). This research topic does not support the use of canines for testing purposes. Any animal testing would require use of a suitable animal model that would approximate the response of a canine.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Development of Wearable Device for Detecting Biomarkers and Treating Viral and Bacterial Infections - SBIR DHA26BZ01-NV004

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop a non-invasive wearable device that can discretely detect biomarkers for and provide initial broad-spectrum treatment for pan-viral and pan-bacterial infections. If fielded for military use, it may require additional security measures.

Description:

The DHA Strategic Research Plan (SRP): Environmental Exposures (June 2024) lists two capability requirements under the “Assess” and “Treat” capability areas that align with this proposal: Environmental Detection and Health Risk Assessments under Assess and Environmental Exposures Treatment under Treat. In addition, the DHA SRP: Military Infectious Diseases (May 2024) lists three capability requirements under the “Prevent”, “Treat”, and “Enable” capability areas that align with this proposal: Prevention of Military Relevant Endemic and Emerging Infectious Diseases under Prevent, Treatment of Military Relevant Endemic and Emerging Infectious Diseases under Treat, and Core Competencies under Enable.

The Department of the Air Force (DAF) is looking for an advanced, non-invasive (does not break the skin or physically enter the body) wearable device (i.e., flash/continuous glucose style monitoring) capable of qualitatively detecting all-viral and all-bacterial infections using discrete biomarkers for such infections: TRAIL, MxA, CD46, IP-10, PTX3, or other non-blood based biomarkers (saliva, sweat, etc.) for viral infections and CRP, PCT, IL-6, IL-8, CD35, CD55, CD64, pro-ADM, or other non-blood based biomarkers (saliva, sweat, etc.) for bacterial infections. The end goal is a wearable device that discretely detects viral and bacterial infections and renders initial, broad-spectrum anti-viral or anti-bacterial treatment(s) at austere operational environments where no immediate medical countermeasures and no other detection capabilities are available until casualties are evacuated to locations with more robust medical resources for additional and specific differentiation and treatment. At a higher echelon of care, medical personnel must be able to receive data from the device to find out what category of threats (viral or bacterial) has triggered a biomarker detection and what corresponding treatments have been rendered to the affected force before providing more advanced care.

By continuously monitoring validated biomarkers, this device will empower warfighters to detect and respond to biological threats early, enhancing their survivability and operational effectiveness in high-threat theaters and mitigating risks to mission and force. This Air Force Medical Command initiative improves force health protection and ensures mission success. Dual-use functionality of this technology will focus on civilian healthcare systems.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Detection and Treatment of Traumatic Brain Injury in Military Working Dogs - SBIR DHA26BZ01-NV002

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Evaluate previously developed traumatic brain injury (TBI) detection and treatments methods that can be repurposed for use in military working dogs (MWDs) after suffering from battlefield injuries.

Description:

This topic is in support of the DoD Working Dog Strategic Research Plan concerning mitigation, strategies, and treatments for the detection and treatment of TBI.1 Due to the high-risk nature of MWD operations, TBI is a common injury. TBI in the MWD carries an extremely high mortality rate with a prehospital mortality of over 40% for severe TBI cases. It is estimated that 25-40% of all MWD trauma cases are accompanied by TBI, but there is limited data concerning the short- and long-term effects of TBI on the performance and health of the MWD. Current clinical detection methods for TBI in the MWD are by the observation of altered mentation (coma, stupor, depression, lethargy, inappropriate behavior or responses) of the MWD and by use of the modified veterinary Glasgow coma scale or with physical evidence of head trauma (e.g., lacerations, abrasions, bruising, swelling, pain, bleeding from the nose or ears). Current treatment guidelines for TBI in MWDs are largely based on treatment recommendations for humans and are primarily supportive measures to maintain blood pressure, oxygen levels, proper ventilation, and body temperature to mitigate secondary injuries2,3,4. There have been many TBI detection methods and treatment strategies developed for humans that have shown promising results in rodent and large animal models5. The objective of this SBIR is to review research that was performed in rodents, canines, or other large animal models that could be repurposed for the detection and treatment of TBI specifically in MWDs. This research topic does not support the use of canines for testing purposes. Any animal testing would require use of suitable animal model that would approximate the response of a canine.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Military Working Dog Whole Blood Product or Substitute - SBIR DHA26BZ01-NV001

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop a whole blood product or substitute to aid in hemorrhage control for Military Working Dogs (MWD) after battlefield injury that can be used near the point of injury (POI) and throughout the continuum of care to reduce morbidity and mortality.

Description:

This topic is in support of the DoD Working Dog Strategic Research Plan concerning solutions for bleeding control and coagulopathy support.1 The Military Working Dog (MWD) provides a unique and important service to the warfighter. MWDs serve as sentries, perform tracking and patrol, and are used for the detection of explosives. These activities come with a high risk of injury. Uncontrolled hemorrhage following traumatic injury accounts for over 45% of all MWD battlefield deaths2. The current standard of care for hemorrhage in the MWD is to provide immediate fluid therapy through the delivery of crystalloid fluids as the first-line treatment, which is then followed by a synthetic colloid or hypertonic saline. These treatments also require the administration of supplemental oxygen to maintain appropriate oxygen levels and for the survival of the MWD3. To improve their survival rates, the development of a shelf stable canine whole blood product or substitute is a critical priority

The goal of this topic is to develop a stable canine whole blood product and/or substitute (i.e. hemoglobin or polymer oxygen carriers), intended for canine use at both POI and throughout the continuum of care. The product should have a shelf-life of greater than 3 years and be thermal stable (-9℃ to 60℃) to ensure accessibility in operational environments. The product must primarily replicate the oxygen carrier characteristics of whole blood and demonstrate the ability to be used safely and effectively to treat blood loss following traumatic injury. This research topic does not support the use of canines for testing purposes. Any animal testing would require use of suitable animal models that would approximate the response of a canine.

Blood products derived from canine donors must be negative for canine red blood cell antigens DEA 1.1 and DEA 1.2. Donor animals must also be tested for blood borne diseases including canine brucellosis, hemobartonellosis, Borrelia burgdorferi (Lyme disease), Dirofilaria immitis (heartworm disease), Ehrlichia canis, Rocky Mountain spotted fever, Coccidioides immitis, Babesia canis, Babesia gibsoni, Mycoplasma haemocanis and plasma levels of von Willebrand factor. All donor animals must be current on immunizations for canine distemper, hepatitis, parainfluenza, leptospirosis, parvovirus, Bordatella, coronavirus and rabies virus as applicable.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II) - SBIR DHA26BZ01-DV005

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $1.3 Million

Deadline to Apply:

Est. April 29th, 2026.

Objective:

This topic is intended for technology proven ready to move directly into Phase II and accepts Direct to Phase II proposals only. The proposed research will focus on identifying compounds with broad-spectrum activity against clinically relevant fungal pathogens while minimizing toxicity to humans. The primary objective is to identify a small molecule with fungicidal properties that are safe for human use, with FDA clearance.

Description:

Fungal infections represent a growing global health challenge, particularly among immuno-compromised individuals. Invasive fungal infections caused by pathogens such as Candida species, Aspergillus species, Fusarium species, and Mucor species are associated with high morbidity and mortality rates. Fungal infections are associated with 130k hospitalizations, 13 million outpatient visits, and result in a financial burden of $19 billion on the civilian health care sector. Fungal wound infections in particular are also growing challenge for the military. Despite the availability of antifungal agents, current treatments are often limited by toxicity, drug resistance, and narrow-spectrum activity. The emergence of multidrug-resistant fungal strains, such as Candida auris, has further exacerbated the need for novel antifungal therapies. Small molecules with antifungal properties offer a promising avenue for addressing these challenges. Their ability to target specific fungal pathways, combined with the potential for oral bioavailability and low manufacturing costs, makes them ideal candidates for therapeutic development. However, significant scientific and technical hurdles remain with the discovery and optimization of small molecules that are both effective against fungal pathogens and safe for human use. Qualified proposals should identify small molecules with antifungal properties from an existing library. These small molecules should be active against all of the following fungi: Fusarium species, Aspergillus species, Candida auris, or Mucorales species. Qualified molecules will have antifungal activity at nanomolar concentrations. Further, these small molecules must have a cytotoxicity profile similar, or better than Amphotericin B.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

CDMRP: Hearing Restoration Research Program (HRRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The CDMRP Hearing Restoration Research Program (HRRP) FY26 funding opportunity is now anticipated under the FY26 Defense Appropriations Act. This is your chance to secure funding to advance innovative, high-impact research that reduces the burden of hearing loss for Service Members, Veterans, and the general public. Investigators should begin planning now — the official funding opportunity announcements, including pre-application and full application deadlines, will be released soon on Grants.gov.

How much funding would I receive?

The pre-announcement does not specify total program funding. However, individual award mechanisms include funding limits:

• Focused Research Award Level 1: up to $400,000 total costs over a maximum of 2 years.

• Focused Research Award Level 2: up to $1.2 million total costs over a maximum of 3 years.

What could I use the funding for?

HRRP awards can support research that:

• Improves and accelerates translation of auditory regeneration or repair mechanisms.

• Develops diagnostics differentiating sensory, neural, synaptic, or central processing disorders.

• Creates reliable in vitro human models to understand auditory cell mechanisms or evaluate therapies.

Are there any additional benefits I would receive?

• Being part of a CDMRP-managed research portfolio with a history of high-impact biomedical awards.

• Two-tier review that evaluates both scientific quality and programmatic relevance (once FOA is published).

What is the timeline to apply and when would I receive funding?

• Pre-announcement release: February 20, 2026.

• Pre-application and application deadlines: Not yet specified. Formal deadlines will be in the forthcoming FOAs on Grants.gov.

Where does this funding come from?

Funding is provided under the Fiscal Year 2026 Defense Appropriations Act and administered by the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC) through the Congressionally Directed Medical Research Programs (CDMRP).

Who is eligible to apply?

• Independent investigators affiliated with an eligible organization are eligible for the HRRP Focused Research Award mechanisms.

• Full eligibility details will be defined in the forthcoming FOAs on Grants.gov.

What companies and projects are likely to win?

Not specified in the pre-announcement. Detailed selection criteria and program priorities will be in the formal FOAs.

Are there any restrictions I should know about?

• Applications must conform to the requirements in the official funding opportunity announcements once posted.

• Investigators should not interpret this pre-announcement as a promise of funding.

How long will it take me to prepare an application?

Not specified in the pre-announcement. However, investigators should begin planning now to align with the anticipated FOA release and competitive review timeline.

How can BW&CO help?

BW&CO can assist with:

• Interpreting eligibility and program priorities once the FOA is released.

• Drafting compelling pre-applications and full applications that align with CDMRP review criteria.

• Developing budgets and milestones that fit award mechanisms and funding levels.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Vision Research Program (VRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Urgent Opportunity: The Vision Research Program (VRP) has released a pre-announcement for FY26 anticipated funding opportunities as part of the Congressionally Directed Medical Research Programs. These pre-announcements are meant to help investigators plan now — full funding opportunity announcements (FOAs) with deadlines will be posted soon on Grants.gov.

Key Opportunity: Prepare your research ideas targeting military exposure-related visual injury and treatment now — this program will fund high-impact research that advances understanding, diagnosis, treatment, stabilization, and restoration of vision after combat and operational injuries.

How much funding would I receive?

The pre-announcement does not specify total program funding.

Funding by mechanism in the anticipated FOA (for individual awards):

• Clinical Trial Award: up to approximately $2.6M total costs (max 3 years)

• Investigator-Initiated Research Award:

  • Funding Level 1: up to $400,000 total costs (max 2 years)

  • Funding Level 2: up to $1.2M total costs (max 3 years)

• Translational Research Award: up to $1.6M total costs (max 3 years)

• Mentored Clinical Research Award: up to $75,000 total costs (max 1.5 years)

What could I use the funding for?

Funding will support:

• Understanding and treating eye injury or visual dysfunction caused by military exposures.

• Improving diagnosis, stabilization, and treatment of eye injuries in austere and prolonged care environments.

• Restoring visual function after military exposure-related vision loss or severe impairment.

Specific allowable uses will be detailed in the full FOA.

Are there any additional benefits I would receive?

• Being part of a CDMRP-managed research portfolio with a history of high-impact biomedical awards.

• Two-tier review that evaluates both scientific quality and programmatic relevance (once FOA is published).

What is the timeline to apply and when would I receive funding?

• Pre-announcement released: February 20, 2026.

• Full FOA with deadlines: Not yet published — will appear on Grants.gov.

• Pre-application and application deadlines: Will be in the FOA.

Where does this funding come from?

Funding is provided by the FY26 Defense Appropriations Act, as part of the Congressionally Directed Medical Research Programs (CDMRP) managed by the Defense Health Agency Research and Development / Medical Research and Development Command (DHA R&D-MRDC).

Who is eligible to apply?

Eligibility requirements will be defined in the full FOA, not in this pre-announcement.

What companies and projects are likely to win?

Programs with strong relevance to combat and operational vision injury.

1. Projects aligned with diagnosis, acute care stabilization, and visual function restoration.

2. Investigators with evidence of clinical relevance and translational potential.

Are there any restrictions I should know about?

• The pre-announcement is not a promise or obligation for awards.

• Applicants must wait for the full FOA to understand eligibility, submission requirements, and restrictions.

How long will it take me to prepare an application?

Planning should begin now, as the pre-announcement is intended to give time for idea development.

How can BW&CO help?

BW&CO can:

• Translate the full FOA into CEO-ready website copy once published.

• Map your project to the right mechanisms (e.g., clinical vs. translational).

• Prepare submission strategy, narrative, and budget.

• Support compliance with CDMRP requirements and two-tier review expectations.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Peer Reviewed Cancer Research Program (PRCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Peer Reviewed Cancer Research Program (PRCRP) Pre-Announcement invites investigators to prepare for upcoming funding opportunities for innovative, high-impact cancer research that supports military health and mission readiness. Final Funding Opportunity Announcements (FOAs) with deadlines will be posted on Grants.gov; investigators should begin planning now. The deadline for application submissions is not yet specified in this pre-announcement.

How much funding would I receive?

Maximum allowable funding varies by award mechanism as anticipated for FY26:

• Clinical Trial Award: up to $4.5 M total costs

• Idea Award: up to $600,000 total costs

• Impact Award: up to $1.5 M (single PI) or $2 M (Partnering PI)
  Note: These are maximums; actual amounts depend on the final FOA.

What could I use the funding for?

Funding supports:

• Clinical trials that advance preclinical research and improve cancer care.

• Innovative basic research that may introduce new paradigms (Idea Award).

• Mature, high-impact hypothesis-driven research with potential near-term impact.

• Applications must address one of the PRCRP topic areas and at least one Military Health Focus Area related to environmental exposures, mission readiness, and gaps in prevention, detection, treatment, or survivorship.

Are there any additional benefits I would receive?

• Alignment with congressional priorities for military health and cancer research.

• Inclusion in the CDMRP funding ecosystem with access to eBRAP pre-application processes and NIH/Grants.gov submission systems.

What is the timeline to apply and when would I receive funding?

• Application deadlines: Not yet specified (will be in final FOAs on Grants.gov).

• Investigators must first submit a pre-proposal via eBRAP before full application.

• Final FOAs will define all submission dates once released.

Where does this funding come from?

Funding is provided by the FY26 Defense Appropriations Act to the Congressionally Directed Medical Research Programs, managed by the Defense Health Agency Research and Development, Medical Research and Development Command.

Who is eligible to apply?

Eligibility varies by mechanism but generally includes independent investigators at all career stages. For Idea Awards, the Early-Career Investigator option is open to those within 7 years of last training and below associate professor rank. Exact institutional eligibility requirements will be in the final FOA.

What companies and projects are likely to win?

Applications that:

• Address at least one FY26 PRCRP Topic Area not covered by other CDMRP cancer programs.

• Clearly relate proposed work to military health, mission readiness, and beneficiary cancer needs.

• Demonstrate scientific merit, innovation/potential impact, and relevance to program goals.
  Projects bridging gaps in prevention, diagnosis, treatment, quality of life, or survivorship in military populations will be competitive.

Are there any restrictions I should know about?

• Final FOAs will specify complete eligibility, topic focus, budget limits, and submission requirements.

• Pre-announcement does not guarantee funding; investigators must wait for formal FOAs on Grants.gov.

How long will it take me to prepare an application?

Preparation time depends on the mechanism:

• Clinical trials need completed preclinical data and IND/IDE submissions before application.

• Idea and Impact Award proposals require scientific groundwork and alignment with topic areas.
  Plan several weeks to months for strategy, pre-proposal, and full application drafts once FOAs are released.

How can BW&CO help?

BW&CO can:

• Interpret final FOAs and clarify topic areas.

• Craft compelling research narratives tied to military health priorities.

• Assist with budgeting, required forms, and eBRAP/Grants.gov submissions.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Melanoma Research Program (MRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Congressionally Directed Medical Research Programs (CDMRP) released a pre-announcement for anticipated FY26 Melanoma Research Program (MRP) funding opportunities. This notice signals that new award mechanisms and funding will be forthcoming, but the application deadlines are not yet specified; they will be published in the formal Funding Opportunity Announcement (FOA) on Grants.gov and eBRAP once available.

How much funding would I receive?

• Idea Award: Maximum total costs up to $560,000 (period up to 2 years).

• Melanoma Academy Scholar Award: Maximum total costs up to $770,000 (period up to 3 years).

• Team Science Award: Maximum total costs up to $2.1 million (period up to 3 years).

• Focused Program Award – Rare Melanomas: Maximum total costs up to $2.8 million (period up to 4 years).

• Survivorship Research Award: Maximum total costs up to $1.015 million (period up to 3 years).

What could I use the funding for?

• All awards must address one or more of the FY26 MRP focus areas:

  • Identify, understand, and mitigate melanoma risk factors and develop biomarkers.

  • Develop detection/diagnosis technologies that improve risk stratification.

  • Define mechanisms of initiation, response/resistance to therapy, progression, recurrence, metastasis.

  • Develop new preclinical models representing disease evolution (cutaneous and rare subtypes).

  • Address unmet needs across cancer research spectrum for rare melanomas.

  • Address psychological/social impacts, quality of life, treatment toxicities, and survivorship issues.

Are there any additional benefits I would receive?

• Melanoma Academy Scholar Award includes mentoring, national networking, and structured career support.

What is the timeline to apply and when would I receive funding?

• The pre-announcement is available now (released February 18, 2026); full FOAs will be released later on Grants.gov.

• Exact pre-application and application deadlines will be specified in those FOAs—not yet provided in the pre-announcement.

• Funding start dates will depend on the FOA timeline and award negotiations—not specified in the pre-announcement.

Where does this funding come from?

Funding is provided through the FY26 Defense Appropriations Act and administered by the Defense Health Agency Research and Development / Medical Research and Development Command (MRDC) under the CDMRP.

Who is eligible to apply?

Eligibility for each award mechanism is defined in the full FOA. From the pre-announcement:

• Idea Award: Investigators at or above the postdoctoral level (or equivalent).

• Melanoma Academy Scholar Award: Investigators within 7 years of first faculty appointment.

• Team Science Award: Independent investigators (Assistant Professor level or equivalent).

• Focused Program Award – Rare Melanomas: Initiating PI at Associate Professor level or equivalent; Partnering PIs at Assistant Professor level or above.

• Survivorship Research Award: Independent investigators (Assistant Professor level or equivalent).

Detailed eligibility criteria (organization types, citizenship, cost share, etc.) will be in the FOA—not specified in the pre-announcement.

What companies and projects are likely to win?

Not specified in the pre-announcement; CDMRP typically funds high-risk, high-gain research that aligns tightly with the listed focus areas and relevance to melanoma biology, detection, survivorship, and unmet clinical needs. Projects that integrate multidisciplinary approaches or include military/VA relevance are typically competitive, but the solicitation does not provide explicit criteria.

Are there any restrictions I should know about?

• The pre-announcement states that submission does not guarantee FOAs or funding.

• All applications must adhere to the final FOA instructions on Grants.gov when released.

• Preliminary data expectations, animal or human subjects requirements, and allowable costs will be defined in the FOA—not yet specified here.

How long will it take me to prepare an application?

• Not specified in the pre-announcement because deadlines are not yet posted. Generally, planning should begin now given the complexity of CDMRP submissions and required pre-applications (e.g., eBRAP).

How can BW&CO help?

BW&CO can:

• Monitor the release of the official FOA and deadlines.

• Translate the FOA into a targeted application strategy.

• Help craft compelling project narrative, budget, and compliance sections.

• Provide review, editing, and submission support to maximize competitiveness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Multiple Sclerosis Research Program (MSRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The CDMRP Multiple Sclerosis Research Program (MSRP) Pre-Announcement for FY26 provides early notice of anticipated funding opportunities for innovative research on multiple sclerosis. This announcement is not the official funding solicitation — it is intended to give investigators advance insight to begin planning competitive proposals. Final Funding Opportunity Announcements (FOAs) with submission deadlines will be posted later on Grants.gov and eBRAP.

How much funding would I receive?

The MSRP pre-announcement outlines proposed award types with maximum allowable funding levels (total costs, including direct and indirect):

• Clinical Trial Award
  • Level 1: up to $1,000,000 over up to 3 years
  • Level 2: up to $2,000,000 over up to 4 years

• Early Investigator Research Award
  • Up to $300,000 over up to 2 years

• Exploration – Hypothesis Development Award
  • Up to $250,000 over up to 2 years

• Investigator-Initiated Research Award
  • Up to $1,000,000 over up to 3 years

These amounts represent maximums anticipated for each mechanism; they are not guaranteed awards until the official FOA is released.

What could I use the funding for?

Funding is intended to support multiple sclerosis research, across a variety of scientific aims depending on award mechanism. Key areas include:

Clinical Trial Award

• Conduct proof-of-principle or early-phase clinical trials with potential to improve clinical outcomes or inform translational feasibility.

• Research must focus on treatment approaches or evidence relevant to MS patient populations.

Early Investigator Research Award

• Support early-career investigators initiating MS research.

• Projects may explore CNS repair, protection, regeneration, correlates of disease activity, symptomatic measurements, or disease mechanisms.

Exploration – Hypothesis Development Award

• Support high-risk, high-gain conceptual studies, not clinical trials.

• Encourages innovative ideas across MS biology, disease progression, symptoms, and repair.

Investigator-Initiated Research Award

• Support rigorous, investigator-driven MS studies with strong preliminary data.

• Applies to new and established researchers; clinical trials are excluded.

Are there any additional benefits I would receive?

• This pre-announcement gives lead time to plan research concepts and collaborations ahead of official FOA release.

• Investigators can prepare strategic proposals, letters of intent, and consortium plans before deadlines are published.

• Awardees likely benefit from CDMRP’s two-tier review process aligning scientific merit with program relevance.

What is the timeline to apply and when would I receive funding?

• Application deadlines will not be in this pre-announcement.
  The CDMRP plans to release full FOAs on Grants.gov and eBRAP with specific pre-application and application due dates.

• Funding decisions and award issuance will occur after review of submitted applications (typically several months after the final due date, depending on CDMRP schedule and appropriations).

Where does this funding come from?

The MSRP is funded through the Department of Defense Congressionally Directed Medical Research Programs (CDMRP), which received appropriations as part of the FY26 Defense Appropriations Act. The CDMRP oversees research across many disease areas, including multiple sclerosis.

Who is eligible to apply?

Eligibility varies by award mechanism, but generally:

• Clinical Trial Award: Independent investigators at all career levels.

• Early Investigator Research Award: Early stage investigators (mentored; specific experience requirements).

• Exploration and Investigator-Initiated Awards: Independent investigators at all career stages; specific criteria on prior funding or experience may apply.

Final eligibility details will be in the official FOA.

What companies and projects are likely to win?

Projects likely to be competitive will:

• Align strongly with MSRP focus areas (repair, neuroprotection, symptom biology, clinical intervention).

• Demonstrate rigorous methods, clear impact, and feasibility.

• Include strong preliminary data (where required).

• Address CDMRP priorities in multiple sclerosis research.

Are there any restrictions I should know about?

• The pre-announcement is not a funding solicitation — award cannot be applied for until FOAs are released.

• Clinical trials must meet relevant definitions and follow regulatory requirements.

• Some award types exclude clinical trials or have career stage restrictions.

How long will it take me to prepare an application?

• Planning ahead based on this pre-announcement is recommended.

• Actual FOA publication will define exact due dates, which determine preparation time.

• Early strategic planning (e.g., consortium building, preliminary data generation, letters of intent) will speed application development.

How can BW&CO help?

If you’re seeking professional proposal support, experts like BW&CO Consulting can help you:

• Interpret the pre-announcement and upcoming FOA

• Identify optimal award mechanisms

• Plan research strategy and draft proposals

• Prepare budgets and compliance documents

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Tuberous Sclerosis Complex Research Program (TSCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The CDMRP has issued a pre-announcement for anticipated Fiscal Year 2026 TSCRP funding opportunities to support high-impact research in Tuberous Sclerosis Complex (TSC). This early notice gives researchers time to plan and refine ideas. The full Funding Opportunity Announcement (FOA), including deadlines and submission details, will be posted on Grants.gov in the coming weeks. Investigators should not interpret this pre-announcement as a funding guarantee.

How much funding would I receive?

While exact award amounts are not official until FOAs are posted, the TSCRP pre-announcement outlines three mechanisms with indicative elements:

1. Clinical Translational Research Award

• Supports studies that move promising research closer to clinical application.

• Includes potential pilot clinical trials, biomarker development, and clinical endpoint work.

• Eligible PIs include independent investigators and advanced practice clinical personnel (e.g., genetic counselors, nurses) for clinical care-focused proposals.

• Maximum duration: 3 years

• Estimated total costs: up to ~$1.6M single PI / ~$1.9M with Partnering PI option (pending FOA).

2. Exploration – Hypothesis Development Award

• For high-risk, high-gain ideas in early stages.

• Study designs must be innovative but do not necessarily require preliminary data.

• Clinical subject work must meet human-subjects protection requirements.

• Maximum duration: 2 years

• Estimated total costs: up to ~$350K (pending FOA).

3. Idea Development Award

• Supports new or cross-disciplinary ideas with preliminary data.

• Includes specific options for new-to-field investigators transitioning into TSC research.

• Maximum duration: 3 years

• Estimated total costs: up to ~$800K (pending FOA).

Note: These figures and durations are as presented in the pre-announcement and may differ slightly in the final FOA.

What could I use the funding for?

Applications must address at least one of the following TSCRP priorities:

• Neuropsychiatric aspects of TSC: Understanding, preventing, and treating TSC-associated neuropsychiatric disorders (e.g., behavioral, pharmacological, surgical interventions).

• Tumors and cysts: Preventing or eradicating TSC-related tumors such as angiomyolipomas, subependymal giant cell astrocytoma (SEGA), and lymphangioleiomyomatosis (LAM), including mechanistic insights into TSC signaling pathways.

• Epilepsy associated with TSC: Prevention, improved treatment, and mitigation of adverse neurodevelopmental outcomes.

• Diagnostic & therapeutic technologies: Development or testing of tools and technologies that improve clinical outcomes in TSC.

• Maternal-fetal & reproductive health in TSC: Mechanisms or care improvements affecting women with TSC or LAM and their infants.

Are there any additional benefits I would receive?

FY26 SCIRP includes an Early-Career Partnership Option across all award mechanisms, designed to:

• Encourage collaboration between established and emerging investigators.

• Provide two individual awards under a single project with separate budgets.

• Support career development while increasing research capacity.

What is the timeline to apply and when would I receive funding?

Pre-announcement release: February 17, 2026

1. Formal Funding Opportunity Announcements (FOAs): To be posted on Grants.gov and CDMRP as soon as they are finalized. Pre-applications and full application deadlines will be included in those FOAs.

2. Funding start: After application review and award selection (dates will be provided in individual FOAs).

Where does this funding come from?

Funding is authorized by the FY26 Defense Appropriations Act, which appropriated funds to the CDMRP for a wide range of research programs, including the TSCRP.

Who is eligible to apply?

Eligibility will be defined in each FOA, but CDMRP programs typically allow:

• Independent investigators at all career levels.

• Clinical and translational researchers with relevant expertise.

• Multiple institutional types (academic, nonprofit, clinical).

(Final eligibility criteria will appear in the specific FOAs once posted.)

What companies and projects are likely to win?

Competitive applications typically:

• Align clearly with one or more of the TSCRP focus areas.

• Show strong scientific rationale and potential for impact on TSC care or understanding.

• Include translational significance or potential to advance clinical outcomes.

Are there any restrictions I should know about?

• The pre-announcement is not a guarantee of funding or a FOA; investigators cannot submit applications based on it alone.

• Formal submission instructions, eligibility, and restrictions will be defined in forthcoming FOAs.

How long will it take me to prepare an application?

Time needed varies by project, but standard CDMRP FOAs often allow several weeks to months for:

• Letter of intent (if required).

• Pre-application submission.

• Full application preparation.

Tip: Begin early by reviewing past TSCRP FOAs and planning collaborative teams, hypotheses, and preliminary data.

How can BW&CO help?

If you need assistance with strategy, positioning against TSCRP priorities, or full proposal writing support, BW&CO can:

• Align your research aims to TSCRP’s priority areas.

• Draft compelling abstracts and narratives tailored to CDMRP review criteria.

• Provide budget and compliance support based on CDMRP rules.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Spinal Cord Injury Research Program (SCIRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

On February 17, 2026, the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) released the Spinal Cord Injury Research Program (SCIRP) anticipated funding opportunities for Fiscal Year 2026 (FY26), providing researchers with key priorities and award mechanisms to plan applications ahead of full Funding Opportunity Announcements. This pre-announcement outlines the SCIRP’s research goals and award structures, including a strong emphasis on clinical, translational, and investigator-initiated research in spinal cord injury. Final Funding Opportunity Announcements with deadlines will be posted on Grants.gov once available.

How much funding would I receive?

The pre-announcement specifies award maximums for each mechanism (total costs, including direct and indirect):

• Clinical Trial Award

  • Single PI: up to $4.8M over 4 years

  • Early-Career Partnership Option: up to $4.96M over 4 years

• Clinical Translation Research Award

  • Single PI: up to $2.0M over 3 years

  • Early-Career Partnership: up to $2.16M over 3 years

• Translational Research Award

  • Single PI: up to $2.0M over 3 years

  • Early-Career Partnership: up to $2.16M over 3 years

• Investigator-Initiated Research Award

  • Single PI: up to $800,000 over 3 years

  • Early-Career Partnership: up to $960,000 over 3 years

What could I use the funding for?

Funding supports research that advances spinal cord injury (SCI) understanding, treatment, and care across four major areas:

• Acute Injury Intervention

  • Develop and test interventions to protect spinal cord tissue after injury with measurable neurological benefit.

• Secondary Health Effects

  • Research interventions addressing long-term consequences of SCI across the lifespan.

• Psychosocial Issues

  • Test strategies for promoting psychosocial well-being tailored to people with SCI and their families/care partners.

• Rehabilitation and Regeneration

  • Advance rehabilitation strategies and regenerative/neuroplastic approaches for improved functional recovery.

Are there any additional benefits I would receive?

FY26 SCIRP includes an Early-Career Partnership Option across all award mechanisms, designed to:

• Encourage collaboration between established and emerging investigators.

• Provide two individual awards under a single project with separate budgets.

• Support career development while increasing research capacity.

What is the timeline to apply and when would I receive funding?

Pre-Announcement (released): February 17, 2026.

Next Steps:

• Full Funding Opportunity Announcements (FOAs) will be posted on Grants.gov and contain specific pre-application and application deadlines.

• Applicants must submit a pre-application (via eBRAP) prior to the full application.

• Funding awards start after review and final selection dates in the FOAs. (Exact dates not yet published.)

Where does this funding come from?

SCIRP is part of the CDMRP, a Department of Defense research portfolio funded through the Defense Appropriations Act. For FY26, the CDMRP received appropriations to fund 34 research programs including SCIRP.

Who is eligible to apply?

Eligibility varies by award mechanism, but in general:

• Independent investigators at all career levels are eligible for single PI awards.

• Early-Career Partnership Option requires one early-career investigator meeting defined experience criteria.

Specific eligibility criteria and organizational requirements will be detailed in the FOAs. al relevance.

What companies and projects are likely to win?

Projects most competitive will:

• Directly address one or more SCIRP priority research areas.

• Demonstrate scientific impact, innovation, and relevance to SCI outcomes.

• Include clear paths to clinical or translational impact (as specified by mechanism).

• (For Early-Career Partnership) show strong mentorship and collaborative planning.

Are there any restrictions I should know about?

• Pre-applications are required before full applications.

• All research must conform to final FOA requirements once released.

• Funding opportunity terms, budgets, eligible costs, and indirect cost policies will be specified in FOAs.

How long will it take me to prepare an application?

Preparation time depends on research maturity and team readiness, but investigators should factor in:

• Time to align research with SCIRP priorities.

• Drafting a competitive pre-application (often weeks before FOA deadlines).

• Preparing full application (including budgets, human subjects, partnerships).
  (SCIRP pre-announcement is intended to give applicants advance planning time.)

How can BW&CO help?

If you need assistance with strategy, positioning against SCIRP priorities, or full proposal writing support, BW&CO can:

• Align your research aims to SCIRP’s priority areas.

• Draft compelling abstracts and narratives tailored to CDMRP review criteria.

• Provide budget and compliance support based on CDMRP rules.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Arthritis Research Program (ATRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Arthritis Research Program (ATRP) has released its anticipated funding opportunities for Fiscal Year 2026, funded through the Department of Defense’s FY26 Defense Appropriations Act and managed by the CDMRP. This pre-announcement is meant to help investigators prepare competitive proposals ahead of the official Funding Opportunity Announcements (FOAs). Deadlines for pre-applications and full applications will be included in the upcoming FOAs on Grants.gov once released.

How much funding would I receive?

While the total program budget for ATRP isn’t specified in the pre-announcement itself, the FY26 DoD appropriations provide funding for the ATRP as part of a broader portfolio that includes a ~$10 M allocation for arthritis research.

Per award (anticipated levels):

• Clinical Research Award

  • Research Level 1: Up to $1.3 M total costs over up to 4 years.

  • Research Level 2: Up to $3.25 M total costs over up to 4 years.

• Translational Research Award

  • Up to $800,000 total costs over up to 3 years.
    All awards count direct + indirect costs.

What could I use the funding for?

Funding is structured to support clinically relevant arthritis research:

Prevention & Early Diagnosis

• Identify factors predicting disease onset/progression

• Develop technologies or solutions for arthritis prevention.

Treatment & Burden Mitigation

• Topic 1: Evaluate interventions or strategies that alleviate pain/symptoms, improve function, address psychosocial factors, comorbidities, or pathologic disease burden.

• Topic 2: Develop new solutions targeting similar multifactorial elements of arthritis.

Translated into potential research areas:

• Pilot studies or full clinical trials (clinical research)

• Translational projects moving discoveries toward clinical application (without supporting clinical trials)

Are there any additional benefits I would receive?

• Being part of a CDMRP program provides two-tier review with both scientific and programmatic relevance evaluation (via eBRAP/Grants.gov processes).

• Opportunities to influence care and policy with clinically actionable outputs.

• Access to broader CDMRP support resources and network.

What is the timeline to apply and when would I receive funding?

• This is a pre-announcement only. Formal FOAs with pre-application and full application deadlines will be posted to Grants.gov and eBRAP later.

• Funding timeline (award start to end) aligns with award type (up to 3–4 years).

Where does this funding come from?

Funding comes from the FY26 Defense Appropriations Act, via the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP), managed through the Defense Health Agency Research and Development Command (DHA R&D-MRDC).

Who is eligible to apply?

• Independent investigators at all academic levels or equivalents can apply for all award types.

• Clinical awards expect research aligned with program focus areas.

• Translational awards require preliminary data and aim to move findings toward clinical relevance.

What companies and projects are likely to win?

Likely competitive applicants will:

• Address prevention, early diagnosis, treatment efficacy, or multifactorial burden mitigation of arthritis.

• Show strong preliminary data, especially for translational and clinical research.

• Demonstrate clinical relevance and potential to improve patient outcomes.

• Include multidisciplinary teams with community collaborators (patients/care partners) for applicability.

Are there any restrictions I should know about?

• Pre-announcement is not a funding obligation or contract — final requirements and eligibility criteria will be defined in FOAs.

• Clinical trials require appropriate planning and justification.

• Applications for clinical research must include relevant preliminary/published data.

How long will it take me to prepare an application?

• Preparation timelines vary by mechanism:

  • Clinical Research Awards may take months to draft due to data, design, and collaborator requirements.

  • Translational Awards also require solid preliminary evidence.

  • Plan ahead for eBRAP pre-applications and revision cycles before full submission. (Recommended: map to FOA deadlines once published.)

How can BW&CO help?

BW&CO could support you by:

• Interpret the FOA once published and align your research to program priorities.

• Develop competitive research and budget narratives.

• Coordinate pre-application eBRAP submission and compliance checks.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Amyotrophic Lateral Sclerosis Research Program (ALSRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The CDMRP Amyotrophic Lateral Sclerosis Research Program (ALSRP) released a pre-announcement on February 13, 2026 outlining anticipated FY26 funding opportunities. This pre-announcement is not a funding solicitation — rather, it gives investigators advanced insight to begin planning and developing ideas ahead of the full Funding Opportunity Announcements (FOAs) to be posted later on Grants.gov and eBRAP. Actual deadlines (pre-application and application) will only be available in the final FOAs once they are released — this pre-announcement does not set them.

How much funding would I receive?

The pre-announcement lists maximum allowable funding by mechanism (total costs):

• Clinical Outcomes and Biomarkers Award: up to $1.0M over up to 3 years

• Pilot Clinical Trial Award: up to $2.8M over up to 3 years

• Therapeutic Development Award: up to $2.0M over up to 3 years

• Therapeutic Idea Award: up to $840,000 over up to 2 years

Final program appropriations for ALSRP in FY26 are part of the CDMRP portfolio; historically this has been in the tens of millions — for example, FY25 saw ~$40M allocated.

What could I use the funding for?

Funding supports distinct research areas that align with ALS therapeutic development and clinical impact:

A) Clinical Outcomes and Biomarkers Award

• Develop/validate clinical outcomes or biomarkers to improve ALS clinical trials.

• May include clinician-, observer-, or patient-reported measures and performance outcomes.

• Supports non-interventional biospecimen/data collection (may be parallel to ongoing trials).

B) Pilot Clinical Trial Award

• Early-stage clinical trials with therapeutic efficacy or biological outcome measures.

• Therapeutic interventions must incorporate biomarker-driven designs.

C) Therapeutic Development Award

• Preclinical validation / IND-enabling studies of ALS therapeutics with proof-of-concept data.

• Biomarker development included to support future clinical design.

D) Therapeutic Idea Award

• Novel, high-risk/high-gain hypothesis-driven research aimed at ALS therapy discovery.

• Must include biomarker rationale relevant to eventual clinical trials.

Are there any additional benefits I would receive?

The pre-announcement itself does not specify additional benefits such as training supplements, travel, or workshops. Historically, CDMRP programs may offer resources like investigator workshops and programmatic feedback, but this will be detailed in the final FOAs.

What is the timeline to apply and when would I receive funding?

• Current status: This is a pre-announcement — exact pre-application and application deadlines will be in the forthcoming FOAs on Grants.gov.

• Recommendation: Begin planning now; monitor CDMRP and Grants.gov for FOA release.

• Funding start dates and award notifications will depend on those FOA schedules.

Where does this funding come from?

The ALSRP is funded through the FY26 Defense Appropriations Act and administered by the Congressionally Directed Medical Research Programs under the Defense Health Agency Research and Development / Medical Research and Development Command.

Who is eligible to apply?

Eligibility across mechanisms typically includes independent investigators at all academic levels, or equivalent. Specific institutional eligibility and PI requirements will be defined in the FOAs.

What companies and projects are likely to win?

Competitive applicants are those who:

• Align closely with the intent and scope of each mechanism (clinical outcomes, biomarker rigor, early trials, or therapeutic innovation).

• Propose biomarker-driven strategies that clearly inform later-stage clinical development.

• Build strong community collaboration plans, such as including patient/care partner perspectives.

Final criteria will be in FOA evaluation sections.

Are there any restrictions I should know about?

Restrictions noted in the pre-announcement include:

• Clinical Outcomes and Biomarkers Award does not support interventional clinical trials.

• Therapeutic Idea Award proposals focusing primarily on basic pathophysiology without therapeutic development are not in scope.

• All mechanisms require preproposal submission via eBRAP; full applications are by invitation only.

How long will it take me to prepare an application?

The prep time depends on research maturity, but competitive proposals will typically require:

• Development of a biomarker plan or clinical trial design where applicable.

• Preliminary data for Therapeutic Development scale.

• Engagement of community collaborators early.

Start now — ahead of FOA release — to coordinate team, core facilities, preliminary work, and collaborations.

How can BW&CO help?

BW&CO could support you by:

• Interpreting the final FOAs when released with deadlines and criteria.

• Drafting and refining preproposals and full applications for each mechanism.

• Crafting compelling narrative aligned with CDMRP’s two-tier review process.

• Identifying required biospecimen, clinical, and biomarker components to strengthen impact.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Ovarian Cancer Research Program (OCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) has released a pre-announcement for the FY26 Ovarian Cancer Research Program (OCRP), outlining anticipated funding opportunities. This pre-announcement allows investigators to begin planning competitive proposals ahead of the formal Funding Opportunity Announcements (FOAs) that will be posted on Grants.gov. Applications will be required to address one or more OCRP priority areas, including novel therapies, early detection, quality of life/survivorship, prevention, and basic ovarian cancer biology. Deadlines for pre-applications and full applications will be provided in the FOAs once published.

How much funding would I receive?

Final funding levels and award amounts will be defined in the FY26 FOAs; estimates from similar past OCRP mechanisms include:

• Clinical Trial Award: Up to $2.8M total costs (max) over up to 4 years

• Investigator-Initiated Research Award: Up to $1.05M (single PI) or $1.4M (Partnering PI) over 4 years

• Ovarian Cancer Academy – Early-Career Investigator Award: Up to $1.125M total costs over 4 years

• Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award: Up to $1.4M total costs over 4 years

• Pilot Award: Up to $350,000 total costs over 2 years

These figures reflect anticipated ceilings based on FY25 mechanisms and are subject to confirmation in the FY26 FOAs.

What could I use the funding for?

Funding supports ovarian cancer research aligned with program priorities:

• Clinical trials and translational research

• Proof-of-concept through early phase studies with potential to impact patient care.

• High-impact investigator-driven research

• Basic through translational research (excluding clinical trials under certain mechanisms).

• Early-career investigator development and mentoring

• Interactive training academies for research and clinical trial skills.

• Innovation and preliminary discovery

• Pilot research to generate data for larger projects.

Are there any additional benefits I would receive?

Beyond funding, OCRP mechanisms like the Academy awards provide:

• Mentoring and networking opportunities for early-career researchers.

• Structured professional development through virtual academy experiences.

• Enhanced visibility within the ovarian cancer research community.

What is the timeline to apply and when would I receive funding?

• Application deadlines: Not yet published in the FY26 pre-announcement; FOAs with specific dates will be posted on Grants.gov once released.

• Pre-application & full application deadlines: Will be included in FOAs.

• Award start dates: After review and programmatic selection; typical NIH/DOD timing suggests awards may begin late in FY26 or early FY27, depending on FOA timelines.

Where does this funding come from?

Funding is provided through the FY26 Defense Appropriations Act as part of the DoD’s CDMRP portfolio. OCRP is one of the congressionally directed research programs funded by federal appropriations.

Who is eligible to apply?

Eligibility typically aligns with CDMRP standards:

• Independent investigators (Assistant Professor level or equivalent and above) for most mechanisms.

• Early-career investigators for Academy awards (within defined years of training completion).

• Postdoctoral and clinical fellows for Pilot awards.

Specific eligibility criteria will be detailed in the FY26 FOAs.

What companies and projects are likely to win?

Competitive submissions will:

• Address one or more OCRP areas of emphasis (e.g., early detection, novel therapies, quality of life).

• Demonstrate clinical relevance or strong scientific rationale.

• Present clear pathways to impact ovarian cancer outcomes.

• Align with funding mechanism intent (e.g., ECI development for academy awards).

Projects with rigorous design, transformative potential, and relevance to patient populations are most competitive.

Are there any restrictions I should know about?

Examples based on past OCRP announcements:

• Some mechanisms do not support clinical trials (e.g., Investigator-Initiated Research Award, Pilot Award).

• Applicants may only receive one award per funding cycle from certain mechanisms.

• Pre-application submission is required before full application.

• Investigator eligibility windows apply for early-career awards.

Full restrictions will be in the FY26 FOAs.

How long will it take me to prepare an application?

Preparation time depends on mechanism, but investigators should plan for:

• 8–12 weeks to develop scientific aims, budgets, and letters.

• Additional time if data generation or collaborations are needed.

Starting now will position teams to respond quickly when FOAs are released.

How can BW&CO help?

BW&CO can:

• Interpret OCRP priority areas and align research plans.

• Draft compelling proposals and strong scientific narratives.

• Coordinate submission timelines and compliance packages.

• Support budget and team planning for each mechanism.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Tick-Borne Disease Research Program (TBDRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Fiscal Year 2026 Tick-Borne Disease Research Program (TBDRP) pre-announcement was released by the Congressionally Directed Medical Research Programs (CDMRP) on February 12, 2026. This pre-announcement signals anticipated funding opportunities aimed at high-impact research to prevent, detect, and resolve Lyme disease and other tick-borne diseases that affect Service Members, Veterans, families, and the general public. Funding opportunity announcements (FOAs) — including pre-application and full application deadlines — have not yet been released and must be monitored on Grants.gov and eBRAP.

How much funding would I receive?

Award-specific maximums from the pre-announcement:

• Idea Development Award – Up to $800,000 total costs over up to 3 years.

• Idea Development Award – Career Development Option – Up to $550,000 total costs over up to 3 years.

• Therapeutic/Diagnostic Research Award – Up to $1,325,000 total costs over up to 3 years.

What could I use the funding for?

Funding is intended to support innovative, high-impact research addressing tick-borne diseases. The pre-announcement defines mechanism-specific focus areas:

A) Idea Development Award

Pathogenesis

• Assess interactions among tick-borne pathogens (emphasis Lyme and co-infections)

• Study persistent clinical manifestations (neurologic symptoms encouraged)

• Studies on maternal health, pregnancy outcomes, congenital infections

Treatment

• Proof-of-concept for novel therapeutics or repurposing existing compounds

• Target identification/validation and early refinement of therapeutic candidates

Diagnosis

• Development/optimization of improved diagnostics for:

  • Single or multiple tick-borne pathogens (priority on direct detection of Borrelia burgdorferi)

  • Distinguish active Lyme infection from past exposure

  • Detect/diagnose maternal-to-fetal transmission, including relevant animal models

B) Therapeutic/Diagnostic Research Award

• Treatment – Evaluation/refinement of therapeutic candidates, including PK/PD and toxicology; designed to advance early/preclinical drug development.

• Diagnosis – Validation of novel diagnostics capable of single or multi-pathogen detection, distinguishing active from past infection, and detecting maternal-to-fetal transmission pathways.

Are there any additional benefits I would receive?

• The program explicitly supports career development options for early-career investigators (with mentorship).

• Pre-application requirements and peer review support transparency in mechanism expectations.

What is the timeline to apply and when would I receive funding?

• Application deadlines: Not yet released. The pre-announcement states that FOAs containing specific pre-application and application deadlines will be posted on Grants.gov and through the eBRAP portal once available.

• Funding start: After successful review, awards typically begin in the fiscal year following announcement (FY26), but exact start dates are not yet published.

Where does this funding come from?

Funding for TBDRP is provided by the Fiscal Year 2026 Defense Appropriations Act, and administered by the Defense Health Agency Research and Development / Medical Research and Development Command (CDMRP).

Who is eligible to apply?

Eligibility varies by mechanism. From the pre-announcement:

• Independent investigators at all career levels are eligible for many mechanisms.

• Career Development Option has specific requirements:

  • PI must be within 10 years of terminal degree (with exceptions for residency/family leave)

  • Mentor must be experienced (≥5 year track record in tick-borne disease research)

What companies and projects are likely to win?

Projects that are highly innovative, directly related to the defined focus areas, and translational in nature (with clear clinical relevance) are likely to be competitive. Specifically:

• Approaches that address persistent Lyme disease, novel diagnostics, and novel therapeutic strategies

• Research that demonstrates strong rationale or preliminary data aligned with CDCMRP priorities

• Early-career investigators partnered with experienced mentors (for Career Development Option)

Are there any restrictions I should know about?

• Clinical trials cannot be supported under these mechanisms; human studies are permitted where applicable.

• Full application submission is by invitation only after pre-proposal review.

• Mechanism‐specific eligibility and focus area alignment are strict and will be enforced in the FOA.

How long will it take me to prepare an application?

Preparation time varies significantly by mechanism and institutional support, but given the requirement for pre-proposals, preliminary data, and alignment with specific focus areas, investigators should plan for 6–12 weeks of preparation once the FOA is released. This accounts for drafting, internal review, and compliance checks prior to pre-application submission.

How can BW&CO help?

BW&CO can help you:

• Interpret and map your research to specific TBDRP focus areas

• Develop pre-proposal drafts and strategic research narratives

• Identify data needs and plan for compliant application packages

• Coordinate mentor relationships for career development submissions

• Set milestones to meet pre-application and full application deadlines

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Pancreatic Cancer Research Program (PCARP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Pancreatic Cancer Research Program (PCARP) is anticipated to issue multiple funding opportunities to accelerate impactful research in pancreatic cancer, spanning early detection, supportive care, risk characterization, access to care, metabolic dysregulation, tumor development, biomarkers, and new therapeutics. Investigators should begin planning now—formal Funding Opportunity Announcements (FOAs), deadlines, and application requirements will be posted on Grants.gov once released. This pre-announcement does not obligate funding but signals that awards will be available in FY26.

How much funding would I receive?

Funding varies by mechanism:

• Focused Pilot Award: Up to $300,000 total costs over up to 2 years.

• Idea Development Award: Up to $700,000 total costs over up to 3 years (standard) or $950,000 total costs with Partnering PI Option.

• Translational Research Partnership Award: Up to $1.1 million total costs over up to 3 years.

What could I use the funding for?

Funding supports research that directly addresses one or more of the following PCARP Focus Areas:

Scientific & Clinical Focus Areas

• Early detection research

• Identification and characterization of risk

• Supportive care, quality of life, and patient perspectives

• Healthcare access barriers and care delivery challenges

• Metabolic disruptions (including diabetes, cachexia)

• Tumor development from precursor lesions to metastasis

• Biomarkers for response prediction and management strategies

• Novel therapeutic targets and approaches

Each award mechanism may have specific constraints on what types of work it can support (e.g., some do not fund clinical trials or basic research).

Are there any additional benefits I would receive?

• Early insight into programmatic priorities via this pre-announcement.

• Access to eBRAP system for managing pre-applications.

• Email subscription updates when official FOAs are released.

What is the timeline to apply and when would I receive funding?

• Pre-announcement published: February 12, 2026.

• Official FOAs: To be posted on Grants.gov (dates not yet announced).

• Submission Deadlines: Will be specified in each FOA (pre-application and full application deadlines).

• Funding Start: Following review, award negotiation, and execution (typical CDMRP cycle timing, exact months TBD).

Where does this funding come from?

PCARP is funded through the FY26 Defense Appropriations Act and managed within the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC) as part of the Congressionally Directed Medical Research Programs (CDMRP).

Who is eligible to apply?

Eligibility depends on the award mechanism:

• Focused Pilot Award: Investigators at any career level, including postdoctoral and clinical fellows.

• Idea Development Award: Independent investigators at any career stage; early-career investigators may partner with experienced PIs.

• Translational Research Partnership Award: Independent investigators; postdoctoral/clinical fellows are not eligible.

What companies and projects are likely to win?

Projects most competitive for PCARP will:

• Directly address one or more specified focus areas with strong scientific rationale.

• Demonstrate innovation and potential impact on pancreatic cancer outcomes.

• Align with mechanism goals (e.g., pilot studies for early-stage ideas, partnerships for translational work).

• Include appropriate preliminary data when required.

Are there any restrictions I should know about?

• Focused Pilot Award: No basic research, pre-clinical animal studies, or clinical trials.

• Idea Development & Translational Awards: Clinical trials and some animal work may be restricted or defined in FOA; check carefully.

• Pre-proposal or letter of intent submission is required prior to full application for many mechanisms.

How long will it take me to prepare an application?

Time depends on mechanism and data readiness:

• Focused Pilot Award: Plan ~4–8 weeks for a competitive pre-application and research plan.

• Idea Development & Translational Awards: With required preliminary data, plan ~8–16+ weeks to assemble data, collaborators, and a strong proposal.

Start early given the expected complexity of CDMRP applications.

How can BW&CO help?

BW&CO can help you:

• Interpret future FOA requirements and priorities.

• Structure pre-applications/letters of intent for maximum impact.

• Craft narrative, budget justification, and compliance sections.

• Align scientific aims with program focus areas to increase competitiveness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Compact Oxygen Generation Medical Devices (COGM / COGM-A) – Defense Health Agency (DHA)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Defense Health Agency (DHA) is soliciting prototype proposals to develop compact medical oxygen generation devices for use in austere and expeditionary military environments. This Other Transaction Authority (OTA) program supports the development of FDA-cleared oxygen generation systems for battlefield care and aeromedical evacuation. Proposals are due March 6, 2026.

How much funding would I receive?

Estimated $1-$2 million. The RPP does not specify a minimum or maximum award size. The government anticipates making multiple prototype OTA awards, with funding incrementally obligated over the period of performance. Total award size will depend on proposed scope, schedule, and cost realism.

What could I use the funding for?

The DHA needs to provide medical oxygen solutions in austere environments to treat service members with compromised lung function or injuries requiring oxygen therapy. The WEMT PMO is developing multiple oxygen generation and delivery systems through its Portable Oxygen (O2) program. This program aims to support casualties across all care settings, including evacuation platforms (Roles of Care 1-3 and en route). Development and approval of candidate solutions will adhere to the U.S. Food and Drug Administration (FDA), and other relevant regulatory and industry best practices.

This effort focuses on developing two expeditionary, easy-to-maintain oxygen generation devices meeting Joint Enroute Care Equipment Test Standard and airworthiness standards:

FOCUS AREA #1: Compact Oxygen Generation, Medical (COGM)

• Priority: High

• Primary Use: Role 1 (but still usable across all Roles, including en route care)

• Capabilities: Adjustable flow rate (3-7 lpm minimum, 15 lpm desired) for use with nasal cannulas, face masks, and nebulizers.

• Target Timeline: Regulatory approvals by 2029, procurement by 2031 (shorter timeline preferred)

FOCUS AREA #2: Compact Oxygen Generation, Medical – At Altitude (COGM-A)

• Primary Use: Aeromedical evacuation platforms

• Capabilities: Similar to COGM, but with adjustable flow up to 15 lpm and high-pressure output for ventilators.

• Target Timeline: Regulatory approvals by 2030, procurement by 2032 (shorter timeline preferred)

Are there any additional benefits I would receive?

Beyond the direct funding, awardees gain several strategic advantages:

Government Validation and Credibility:
Selection by the Defense Health Agency signals strong technical credibility and alignment with DoD operational medical priorities—often accelerating trust with military customers, primes, and investors.

Nondilutive Technology Advancement:
This OTA enables companies to mature medical devices without equity dilution, preserving cap table value while advancing toward procurement readiness.

Follow-On Production Potential:
Successful prototypes may lead directly to a follow-on production OTA, reducing acquisition friction and shortening the path to revenue.

Enhanced Defense Market Visibility:
Awardees become part of DHA’s Warfighter Expeditionary Medicine ecosystem, increasing exposure across DoD medical and acquisition communities..

What is the timeline to apply and when would I receive funding?

1. Questions Due: February 6, 2026

2. Proposals Due: March 6, 2026 (5:00 PM EST)

3. Period of Performance:

   • Up to ~24 months for COGM

   • Up to ~36 months for COGM-A

Where does this funding come from?

This program is funded by the U.S. Department of Defense, administered through the Defense Health Agency (DHA) using Prototype Other Transaction Authority (10 U.S.C. §4022).

Who is eligible to apply?

To be eligible, proposals must meet at least one of the following OTA statutory conditions:

• Include a nontraditional defense contractor or nonprofit research institution participating to a significant extent

• All significant participants are small businesses or nontraditional defense contractors

• At least one-third of total project cost is cost-shared by non-government sources

What companies and projects are likely to win?

Proposals are evaluated on three primary factors:

• Strength and feasibility of the technical approach to meeting SOO requirements

• Credibility of the management and execution plan, including regulatory and manufacturing readiness

• Cost realism and completeness of the proposed budget

Projects starting near TRL 4 with a clear path to FDA clearance and military deployment are strongly aligned.

Are there any restrictions I should know about?

• Proposals must comply with FDA medical device regulations

• Foreign collaborators require additional justification

• Participation in malign foreign talent programs is prohibited

• Cost sharing rules apply if nontraditional or small business criteria are not met

• Files must be submitted exactly as instructed; noncompliance may result in elimination

How long will it take me to prepare an application?

Most first-time applicants (without any assistance from BW&CO) should plan for 120–200 hours of effort over 8–12 weeks, including technical writing, budget preparation, and internal reviews.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for $13000 Initial Fee + 5% Success Fee.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Learn more about the program here.